#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0165] Specificity of Prion Detection by saPMCA
#Text=[0166] Specificity of detection is very important for a diagnostic assay.
1-1	0-1	[	_	_	
1-2	1-5	0165	_	_	
1-3	5-6	]	_	_	
1-4	7-18	Specificity	_	_	
1-5	19-21	of	_	_	
1-6	22-27	Prion	_	_	
1-7	28-37	Detection	_	_	
1-8	38-40	by	_	_	
1-9	41-47	saPMCA	_	_	
1-10	48-49	[	_	_	
1-11	49-53	0166	_	_	
1-12	53-54	]	_	_	
1-13	55-66	Specificity	_	_	
1-14	67-69	of	_	_	
1-15	70-79	detection	_	_	
1-16	80-82	is	_	_	
1-17	83-87	very	_	_	
1-18	88-97	important	_	_	
1-19	98-101	for	_	_	
1-20	102-103	a	_	_	
1-21	104-114	diagnostic	_	_	
1-22	115-120	assay	_	_	
1-23	120-121	.	_	_	

#Text=Specificity of cyclic amplification was evaluated in a blind study in which 10 brain samples of scrapie-affected hamsters and 11 samples of healthy animals were subjected to 48 PMCA cycles and PrP.sup.Sc was detected by Western blot analysis after proteinase K (PK) digestion.
2-1	122-133	Specificity	_	_	
2-2	134-136	of	_	_	
2-3	137-143	cyclic	_	_	
2-4	144-157	amplification	_	_	
2-5	158-161	was	_	_	
2-6	162-171	evaluated	_	_	
2-7	172-174	in	_	_	
2-8	175-176	a	_	_	
2-9	177-182	blind	_	_	
2-10	183-188	study	_	_	
2-11	189-191	in	_	_	
2-12	192-197	which	_	_	
2-13	198-200	10	_	_	
2-14	201-206	brain	_	_	
2-15	207-214	samples	_	_	
2-16	215-217	of	_	_	
2-17	218-234	scrapie-affected	_	_	
2-18	235-243	hamsters	_	_	
2-19	244-247	and	_	_	
2-20	248-250	11	_	_	
2-21	251-258	samples	_	_	
2-22	259-261	of	_	_	
2-23	262-269	healthy	_	_	
2-24	270-277	animals	_	_	
2-25	278-282	were	_	_	
2-26	283-292	subjected	_	_	
2-27	293-295	to	_	_	
2-28	296-298	48	_	_	
2-29	299-303	PMCA	_	_	
2-30	304-310	cycles	_	_	
2-31	311-314	and	_	_	
2-32	315-325	PrP.sup.Sc	_	_	
2-33	326-329	was	_	_	
2-34	330-338	detected	_	_	
2-35	339-341	by	_	_	
2-36	342-349	Western	_	_	
2-37	350-354	blot	_	_	
2-38	355-363	analysis	_	_	
2-39	364-369	after	_	_	
2-40	370-380	proteinase	_	_	
2-41	381-382	K	_	_	
2-42	383-384	(	_	_	
2-43	384-386	PK	_	_	
2-44	386-387	)	_	_	
2-45	388-397	digestion	_	_	
2-46	397-398	.	_	_	

#Text=The results showed that, while 100% of the samples derived from sick animals were positive after PMCA, none of the samples coming from normal animals showed any PrP.sup.Sc signal.
3-1	399-402	The	_	_	
3-2	403-410	results	_	_	
3-3	411-417	showed	_	_	
3-4	418-422	that	_	_	
3-5	422-423	,	_	_	
3-6	424-429	while	_	_	
3-7	430-434	100%	_	_	
3-8	435-437	of	_	_	
3-9	438-441	the	_	_	
3-10	442-449	samples	_	_	
3-11	450-457	derived	_	_	
3-12	458-462	from	_	_	
3-13	463-467	sick	_	_	
3-14	468-475	animals	_	_	
3-15	476-480	were	_	_	
3-16	481-489	positive	_	_	
3-17	490-495	after	_	_	
3-18	496-500	PMCA	_	_	
3-19	500-501	,	_	_	
3-20	502-506	none	_	_	
3-21	507-509	of	_	_	
3-22	510-513	the	_	_	
3-23	514-521	samples	_	_	
3-24	522-528	coming	_	_	
3-25	529-533	from	_	_	
3-26	534-540	normal	_	_	
3-27	541-548	animals	_	_	
3-28	549-555	showed	_	_	
3-29	556-559	any	_	_	
3-30	560-570	PrP.sup.Sc	_	_	
3-31	571-577	signal	_	_	
3-32	577-578	.	_	_	

#Text=Out of the 10 positive control samples, 7 corresponded to a 10,000-fold dilution of brain, 2 corresponded to a 50,000-fold dilution and 1 corresponded to a 100,000-fold dilution.
4-1	579-582	Out	_	_	
4-2	583-585	of	_	_	
4-3	586-589	the	_	_	
4-4	590-592	10	_	_	
4-5	593-601	positive	_	_	
4-6	602-609	control	_	_	
4-7	610-617	samples	_	_	
4-8	617-618	,	_	_	
4-9	619-620	7	_	_	
4-10	621-633	corresponded	_	_	
4-11	634-636	to	_	_	
4-12	637-638	a	_	_	
4-13	639-645	10,000	_	_	
4-14	645-646	-	_	_	
4-15	646-650	fold	_	_	
4-16	651-659	dilution	_	_	
4-17	660-662	of	_	_	
4-18	663-668	brain	_	_	
4-19	668-669	,	_	_	
4-20	670-671	2	_	_	
4-21	672-684	corresponded	_	_	
4-22	685-687	to	_	_	
4-23	688-689	a	_	_	
4-24	690-696	50,000	_	_	
4-25	696-697	-	_	_	
4-26	697-701	fold	_	_	
4-27	702-710	dilution	_	_	
4-28	711-714	and	_	_	
4-29	715-716	1	_	_	
4-30	717-729	corresponded	_	_	
4-31	730-732	to	_	_	
4-32	733-734	a	_	_	
4-33	735-742	100,000	_	_	
4-34	742-743	-	_	_	
4-35	743-747	fold	_	_	
4-36	748-756	dilution	_	_	
4-37	756-757	.	_	_	

#Text=None of these 10 samples showed any PrP.sup.Sc signal in Western blot without PMCA amplification (data not shown).
5-1	758-762	None	_	_	
5-2	763-765	of	_	_	
5-3	766-771	these	_	_	
5-4	772-774	10	_	_	
5-5	775-782	samples	_	_	
5-6	783-789	showed	_	_	
5-7	790-793	any	_	_	
5-8	794-804	PrP.sup.Sc	_	_	
5-9	805-811	signal	_	_	
5-10	812-814	in	_	_	
5-11	815-822	Western	_	_	
5-12	823-827	blot	_	_	
5-13	828-835	without	_	_	
5-14	836-840	PMCA	_	_	
5-15	841-854	amplification	_	_	
5-16	855-856	(	_	_	
5-17	856-860	data	_	_	
5-18	861-864	not	_	_	
5-19	865-870	shown	_	_	
5-20	870-871	)	_	_	
5-21	871-872	.	_	_	

#Text=The interpretation of this data is that, under the conditions used, PMCA leads to 100% specificity in PrP.sup.Sc detection.
#Text=[0167] As demonstrated before, the amplification rate using PMCA depends upon the number of incubation/sonication cycles carried out (Saborio et al., 2001).
6-1	873-876	The	_	_	
6-2	877-891	interpretation	_	_	
6-3	892-894	of	_	_	
6-4	895-899	this	_	_	
6-5	900-904	data	_	_	
6-6	905-907	is	_	_	
6-7	908-912	that	_	_	
6-8	912-913	,	_	_	
6-9	914-919	under	_	_	
6-10	920-923	the	_	_	
6-11	924-934	conditions	_	_	
6-12	935-939	used	_	_	
6-13	939-940	,	_	_	
6-14	941-945	PMCA	_	_	
6-15	946-951	leads	_	_	
6-16	952-954	to	_	_	
6-17	955-959	100%	_	_	
6-18	960-971	specificity	_	_	
6-19	972-974	in	_	_	
6-20	975-985	PrP.sup.Sc	_	_	
6-21	986-995	detection	_	_	
6-22	995-996	.	_	_	
6-23	997-998	[	_	_	
6-24	998-1002	0167	_	_	
6-25	1002-1003	]	_	_	
6-26	1004-1006	As	_	_	
6-27	1007-1019	demonstrated	_	_	
6-28	1020-1026	before	_	_	
6-29	1026-1027	,	_	_	
6-30	1028-1031	the	_	_	
6-31	1032-1045	amplification	_	_	
6-32	1046-1050	rate	_	_	
6-33	1051-1056	using	_	_	
6-34	1057-1061	PMCA	_	_	
6-35	1062-1069	depends	_	_	
6-36	1070-1074	upon	_	_	
6-37	1075-1078	the	_	_	
6-38	1079-1085	number	_	_	
6-39	1086-1088	of	_	_	
6-40	1089-1099	incubation	_	_	
6-41	1099-1100	/	_	_	
6-42	1100-1110	sonication	_	_	
6-43	1111-1117	cycles	_	_	
6-44	1118-1125	carried	_	_	
6-45	1126-1129	out	_	_	
6-46	1130-1131	(	_	_	
6-47	1131-1138	Saborio	_	_	
6-48	1139-1141	et	_	_	
6-49	1142-1144	al	_	_	
6-50	1144-1145	.	_	_	
6-51	1145-1146	,	_	_	
6-52	1147-1151	2001	_	_	
6-53	1151-1152	)	_	_	
6-54	1152-1153	.	_	_	

#Text=Thus, the inventors decided to evaluate whether a PrP.sup.Sc-like signal might appear on negative samples after many PMCA cycles.
7-1	1154-1158	Thus	_	_	
7-2	1158-1159	,	_	_	
7-3	1160-1163	the	_	_	
7-4	1164-1173	inventors	_	_	
7-5	1174-1181	decided	_	_	
7-6	1182-1184	to	_	_	
7-7	1185-1193	evaluate	_	_	
7-8	1194-1201	whether	_	_	
7-9	1202-1203	a	_	_	
7-10	1204-1219	PrP.sup.Sc-like	_	_	
7-11	1220-1226	signal	_	_	
7-12	1227-1232	might	_	_	
7-13	1233-1239	appear	_	_	
7-14	1240-1242	on	_	_	
7-15	1243-1251	negative	_	_	
7-16	1252-1259	samples	_	_	
7-17	1260-1265	after	_	_	
7-18	1266-1270	many	_	_	
7-19	1271-1275	PMCA	_	_	
7-20	1276-1282	cycles	_	_	
7-21	1282-1283	.	_	_	

#Text=For this purpose, a 10% healthy hamster brain homogenate in the absence (negative control) or in the presence (positive control) of an aliquot of a 50,000-fold diluted scrapie brain was subjected to 24, 48, 96, or 144 PMCA cycles and PrP.sup.Sc signal detected by Western blot analysis.
8-1	1284-1287	For	_	_	
8-2	1288-1292	this	_	_	
8-3	1293-1300	purpose	_	_	
8-4	1300-1301	,	_	_	
8-5	1302-1303	a	_	_	
8-6	1304-1307	10%	_	_	
8-7	1308-1315	healthy	_	_	
8-8	1316-1323	hamster	_	_	
8-9	1324-1329	brain	_	_	
8-10	1330-1340	homogenate	_	_	
8-11	1341-1343	in	_	_	
8-12	1344-1347	the	_	_	
8-13	1348-1355	absence	_	_	
8-14	1356-1357	(	_	_	
8-15	1357-1365	negative	_	_	
8-16	1366-1373	control	_	_	
8-17	1373-1374	)	_	_	
8-18	1375-1377	or	_	_	
8-19	1378-1380	in	_	_	
8-20	1381-1384	the	_	_	
8-21	1385-1393	presence	_	_	
8-22	1394-1395	(	_	_	
8-23	1395-1403	positive	_	_	
8-24	1404-1411	control	_	_	
8-25	1411-1412	)	_	_	
8-26	1413-1415	of	_	_	
8-27	1416-1418	an	_	_	
8-28	1419-1426	aliquot	_	_	
8-29	1427-1429	of	_	_	
8-30	1430-1431	a	_	_	
8-31	1432-1438	50,000	_	_	
8-32	1438-1439	-	_	_	
8-33	1439-1443	fold	_	_	
8-34	1444-1451	diluted	_	_	
8-35	1452-1459	scrapie	_	_	
8-36	1460-1465	brain	_	_	
8-37	1466-1469	was	_	_	
8-38	1470-1479	subjected	_	_	
8-39	1480-1482	to	_	_	
8-40	1483-1485	24	_	_	
8-41	1485-1486	,	_	_	
8-42	1487-1489	48	_	_	
8-43	1489-1490	,	_	_	
8-44	1491-1493	96	_	_	
8-45	1493-1494	,	_	_	
8-46	1495-1497	or	_	_	
8-47	1498-1501	144	_	_	
8-48	1502-1506	PMCA	_	_	
8-49	1507-1513	cycles	_	_	
8-50	1514-1517	and	_	_	
8-51	1518-1528	PrP.sup.Sc	_	_	
8-52	1529-1535	signal	_	_	
8-53	1536-1544	detected	_	_	
8-54	1545-1547	by	_	_	
8-55	1548-1555	Western	_	_	
8-56	1556-1560	blot	_	_	
8-57	1561-1569	analysis	_	_	
8-58	1569-1570	.	_	_	

#Text=The results clearly indicated that PrP.sup.Sc reactivity was detected only after PMCA in the positive control samples with an intensity that depended upon the number of cycles performed.
9-1	1571-1574	The	_	_	
9-2	1575-1582	results	_	_	
9-3	1583-1590	clearly	_	_	
9-4	1591-1600	indicated	_	_	
9-5	1601-1605	that	_	_	
9-6	1606-1616	PrP.sup.Sc	_	_	
9-7	1617-1627	reactivity	_	_	
9-8	1628-1631	was	_	_	
9-9	1632-1640	detected	_	_	
9-10	1641-1645	only	_	_	
9-11	1646-1651	after	_	_	
9-12	1652-1656	PMCA	_	_	
9-13	1657-1659	in	_	_	
9-14	1660-1663	the	_	_	
9-15	1664-1672	positive	_	_	
9-16	1673-1680	control	_	_	
9-17	1681-1688	samples	_	_	
9-18	1689-1693	with	_	_	
9-19	1694-1696	an	_	_	
9-20	1697-1706	intensity	_	_	
9-21	1707-1711	that	_	_	
9-22	1712-1720	depended	_	_	
9-23	1721-1725	upon	_	_	
9-24	1726-1729	the	_	_	
9-25	1730-1736	number	_	_	
9-26	1737-1739	of	_	_	
9-27	1740-1746	cycles	_	_	
9-28	1747-1756	performed	_	_	
9-29	1756-1757	.	_	_	

#Text=In comparison, in the negative control samples, no PrP.sup.Sc was ever detected, regardless the number of PMCA cycles carried out.
10-1	1758-1760	In	_	_	
10-2	1761-1771	comparison	_	_	
10-3	1771-1772	,	_	_	
10-4	1773-1775	in	_	_	
10-5	1776-1779	the	_	_	
10-6	1780-1788	negative	_	_	
10-7	1789-1796	control	_	_	
10-8	1797-1804	samples	_	_	
10-9	1804-1805	,	_	_	
10-10	1806-1808	no	_	_	
10-11	1809-1819	PrP.sup.Sc	_	_	
10-12	1820-1823	was	_	_	
10-13	1824-1828	ever	_	_	
10-14	1829-1837	detected	_	_	
10-15	1837-1838	,	_	_	
10-16	1839-1849	regardless	_	_	
10-17	1850-1853	the	_	_	
10-18	1854-1860	number	_	_	
10-19	1861-1863	of	_	_	
10-20	1864-1868	PMCA	_	_	
10-21	1869-1875	cycles	_	_	
10-22	1876-1883	carried	_	_	
10-23	1884-1887	out	_	_	
10-24	1887-1888	.	_	_	

#Text=In order to evaluate the relationship between the extent of PrP.sup.Sc formation and the number of PMCA cycles, the inventors attempted to fit the data to a mathematical formula.
11-1	1889-1891	In	_	_	
11-2	1892-1897	order	_	_	
11-3	1898-1900	to	_	_	
11-4	1901-1909	evaluate	_	_	
11-5	1910-1913	the	_	_	
11-6	1914-1926	relationship	_	_	
11-7	1927-1934	between	_	_	
11-8	1935-1938	the	_	_	
11-9	1939-1945	extent	_	_	
11-10	1946-1948	of	_	_	
11-11	1949-1959	PrP.sup.Sc	_	_	
11-12	1960-1969	formation	_	_	
11-13	1970-1973	and	_	_	
11-14	1974-1977	the	_	_	
11-15	1978-1984	number	_	_	
11-16	1985-1987	of	_	_	
11-17	1988-1992	PMCA	_	_	
11-18	1993-1999	cycles	_	_	
11-19	1999-2000	,	_	_	
11-20	2001-2004	the	_	_	
11-21	2005-2014	inventors	_	_	
11-22	2015-2024	attempted	_	_	
11-23	2025-2027	to	_	_	
11-24	2028-2031	fit	_	_	
11-25	2032-2035	the	_	_	
11-26	2036-2040	data	_	_	
11-27	2041-2043	to	_	_	
11-28	2044-2045	a	_	_	
11-29	2046-2058	mathematical	_	_	
11-30	2059-2066	formula	_	_	
11-31	2066-2067	.	_	_	

#Text=Taking into account all the points available (again done by triplicate) the best fitting was obtained with a sigmoidal curve (Equation: signal intensity=1882/(1+e.sup.
12-1	2068-2074	Taking	_	_	
12-2	2075-2079	into	_	_	
12-3	2080-2087	account	_	_	
12-4	2088-2091	all	_	_	
12-5	2092-2095	the	_	_	
12-6	2096-2102	points	_	_	
12-7	2103-2112	available	_	_	
12-8	2113-2114	(	_	_	
12-9	2114-2119	again	_	_	
12-10	2120-2124	done	_	_	
12-11	2125-2127	by	_	_	
12-12	2128-2138	triplicate	_	_	
12-13	2138-2139	)	_	_	
12-14	2140-2143	the	_	_	
12-15	2144-2148	best	_	_	
12-16	2149-2156	fitting	_	_	
12-17	2157-2160	was	_	_	
12-18	2161-2169	obtained	_	_	
12-19	2170-2174	with	_	_	
12-20	2175-2176	a	_	_	
12-21	2177-2186	sigmoidal	_	_	
12-22	2187-2192	curve	_	_	
12-23	2193-2194	(	_	_	
12-24	2194-2202	Equation	_	_	
12-25	2202-2203	:	_	_	
12-26	2204-2210	signal	_	_	
12-27	2211-2220	intensity	_	_	
12-28	2220-2221	=	_	_	
12-29	2221-2225	1882	_	_	
12-30	2225-2226	/	_	_	
12-31	2226-2227	(	_	_	
12-32	2227-2228	1	_	_	
12-33	2228-2229	+	_	_	
12-34	2229-2234	e.sup	_	_	
12-35	2234-2235	.	_	_	

#Text=-(number of cycles-53.6)/21.8), indicating that after an exponential relationship between the extent of conversion and the number of cycles, the formation of new PrP.sup.Sc reaches a plateau.
13-1	2235-2236	-	_	_	
13-2	2236-2237	(	_	_	
13-3	2237-2243	number	_	_	
13-4	2244-2246	of	_	_	
13-5	2247-2253	cycles	_	_	
13-6	2253-2254	-	_	_	
13-7	2254-2258	53.6	_	_	
13-8	2258-2259	)	_	_	
13-9	2259-2260	/	_	_	
13-10	2260-2264	21.8	_	_	
13-11	2264-2265	)	_	_	
13-12	2265-2266	,	_	_	
13-13	2267-2277	indicating	_	_	
13-14	2278-2282	that	_	_	
13-15	2283-2288	after	_	_	
13-16	2289-2291	an	_	_	
13-17	2292-2303	exponential	_	_	
13-18	2304-2316	relationship	_	_	
13-19	2317-2324	between	_	_	
13-20	2325-2328	the	_	_	
13-21	2329-2335	extent	_	_	
13-22	2336-2338	of	_	_	
13-23	2339-2349	conversion	_	_	
13-24	2350-2353	and	_	_	
13-25	2354-2357	the	_	_	
13-26	2358-2364	number	_	_	
13-27	2365-2367	of	_	_	
13-28	2368-2374	cycles	_	_	
13-29	2374-2375	,	_	_	
13-30	2376-2379	the	_	_	
13-31	2380-2389	formation	_	_	
13-32	2390-2392	of	_	_	
13-33	2393-2396	new	_	_	
13-34	2397-2407	PrP.sup.Sc	_	_	
13-35	2408-2415	reaches	_	_	
13-36	2416-2417	a	_	_	
13-37	2418-2425	plateau	_	_	
13-38	2425-2426	.	_	_	

#Text=This plateau can be due to the exhaustion of all PrP.sup.C substrate by conversion into PrP.sup.Sc or to the lost of conversion efficacy by inactivation of the substrate or putative conversion factors after long times of incubation/sonication.
14-1	2427-2431	This	*[1]	15-1[2_1]	
14-2	2432-2439	plateau	*[1]	_	
14-3	2440-2443	can	*[1]	_	
14-4	2444-2446	be	*[1]	_	
14-5	2447-2450	due	*[1]	_	
14-6	2451-2453	to	*[1]	_	
14-7	2454-2457	the	*[1]	_	
14-8	2458-2468	exhaustion	*[1]	_	
14-9	2469-2471	of	*[1]	_	
14-10	2472-2475	all	*[1]	_	
14-11	2476-2485	PrP.sup.C	*[1]	_	
14-12	2486-2495	substrate	*[1]	_	
14-13	2496-2498	by	*[1]	_	
14-14	2499-2509	conversion	*[1]	_	
14-15	2510-2514	into	*[1]	_	
14-16	2515-2525	PrP.sup.Sc	*[1]	_	
14-17	2526-2528	or	*[1]	_	
14-18	2529-2531	to	*[1]	_	
14-19	2532-2535	the	*[1]	_	
14-20	2536-2540	lost	*[1]	_	
14-21	2541-2543	of	*[1]	_	
14-22	2544-2554	conversion	*[1]	_	
14-23	2555-2563	efficacy	*[1]	_	
14-24	2564-2566	by	*[1]	_	
14-25	2567-2579	inactivation	*[1]	_	
14-26	2580-2582	of	*[1]	_	
14-27	2583-2586	the	*[1]	_	
14-28	2587-2596	substrate	*[1]	_	
14-29	2597-2599	or	*[1]	_	
14-30	2600-2608	putative	*[1]	_	
14-31	2609-2619	conversion	*[1]	_	
14-32	2620-2627	factors	*[1]	_	
14-33	2628-2633	after	*[1]	_	
14-34	2634-2638	long	*[1]	_	
14-35	2639-2644	times	*[1]	_	
14-36	2645-2647	of	*[1]	_	
14-37	2648-2658	incubation	*[1]	_	
14-38	2658-2659	/	*[1]	_	
14-39	2659-2669	sonication	*[1]	_	
14-40	2669-2670	.	*[1]	_	

#Text=This problem was resolved by saPMCA.
15-1	2671-2675	This	*[2]	_	
15-2	2676-2683	problem	*[2]	_	
15-3	2684-2687	was	_	_	
15-4	2688-2696	resolved	_	_	
15-5	2697-2699	by	_	_	
15-6	2700-2706	saPMCA	_	_	
15-7	2706-2707	.	_	_	

#Text=When the data was fitted excluding the last time point, the best fit was obtained with an exponential curve (Equation: signal intensity=67/e.sup.0.98(number of cycles)).
16-1	2708-2712	When	_	_	
16-2	2713-2716	the	_	_	
16-3	2717-2721	data	_	_	
16-4	2722-2725	was	_	_	
16-5	2726-2732	fitted	_	_	
16-6	2733-2742	excluding	_	_	
16-7	2743-2746	the	_	_	
16-8	2747-2751	last	_	_	
16-9	2752-2756	time	_	_	
16-10	2757-2762	point	_	_	
16-11	2762-2763	,	_	_	
16-12	2764-2767	the	_	_	
16-13	2768-2772	best	_	_	
16-14	2773-2776	fit	_	_	
16-15	2777-2780	was	_	_	
16-16	2781-2789	obtained	_	_	
16-17	2790-2794	with	_	_	
16-18	2795-2797	an	_	_	
16-19	2798-2809	exponential	_	_	
16-20	2810-2815	curve	_	_	
16-21	2816-2817	(	_	_	
16-22	2817-2825	Equation	_	_	
16-23	2825-2826	:	_	_	
16-24	2827-2833	signal	_	_	
16-25	2834-2843	intensity	_	_	
16-26	2843-2844	=	_	_	
16-27	2844-2846	67	_	_	
16-28	2846-2847	/	_	_	
16-29	2847-2852	e.sup	_	_	
16-30	2852-2857	.0.98	_	_	
16-31	2857-2858	(	_	_	
16-32	2858-2864	number	_	_	
16-33	2865-2867	of	_	_	
16-34	2868-2874	cycles	_	_	
16-35	2874-2875	)	_	_	
16-36	2875-2876	)	_	_	
16-37	2876-2877	.	_	_	

#Text=These findings support the idea of an exponential dependence on the number of PMCA cycles when conversion conditions are not limiting (less than 100 cycles).
#Text=[0168] Specificity was further studied in an even more challenging situation in which several rounds of PMCA were done after diluting the material to refresh the substrate.
17-1	2878-2883	These	_	_	
17-2	2884-2892	findings	_	_	
17-3	2893-2900	support	_	_	
17-4	2901-2904	the	_	_	
17-5	2905-2909	idea	_	_	
17-6	2910-2912	of	_	_	
17-7	2913-2915	an	_	_	
17-8	2916-2927	exponential	_	_	
17-9	2928-2938	dependence	_	_	
17-10	2939-2941	on	_	_	
17-11	2942-2945	the	_	_	
17-12	2946-2952	number	_	_	
17-13	2953-2955	of	_	_	
17-14	2956-2960	PMCA	_	_	
17-15	2961-2967	cycles	_	_	
17-16	2968-2972	when	_	_	
17-17	2973-2983	conversion	_	_	
17-18	2984-2994	conditions	_	_	
17-19	2995-2998	are	_	_	
17-20	2999-3002	not	_	_	
17-21	3003-3011	limiting	_	_	
17-22	3012-3013	(	_	_	
17-23	3013-3017	less	_	_	
17-24	3018-3022	than	_	_	
17-25	3023-3026	100	_	_	
17-26	3027-3033	cycles	_	_	
17-27	3033-3034	)	_	_	
17-28	3034-3035	.	_	_	
17-29	3036-3037	[	_	_	
17-30	3037-3041	0168	_	_	
17-31	3041-3042	]	_	_	
17-32	3043-3054	Specificity	_	_	
17-33	3055-3058	was	_	_	
17-34	3059-3066	further	_	_	
17-35	3067-3074	studied	_	_	
17-36	3075-3077	in	_	_	
17-37	3078-3080	an	_	_	
17-38	3081-3085	even	_	_	
17-39	3086-3090	more	_	_	
17-40	3091-3102	challenging	_	_	
17-41	3103-3112	situation	_	_	
17-42	3113-3115	in	_	_	
17-43	3116-3121	which	_	_	
17-44	3122-3129	several	_	_	
17-45	3130-3136	rounds	_	_	
17-46	3137-3139	of	_	_	
17-47	3140-3144	PMCA	_	_	
17-48	3145-3149	were	_	_	
17-49	3150-3154	done	_	_	
17-50	3155-3160	after	_	_	
17-51	3161-3169	diluting	_	_	
17-52	3170-3173	the	_	_	
17-53	3174-3182	material	_	_	
17-54	3183-3185	to	_	_	
17-55	3186-3193	refresh	_	_	
17-56	3194-3197	the	_	_	
17-57	3198-3207	substrate	_	_	
17-58	3207-3208	.	_	_	

#Text=Brains from healthy hamsters and from animals infected with 263K scrapie were diluted 10.sup.4-fold into a 10% normal hamster brain homogenate.
18-1	3209-3215	Brains	_	_	
18-2	3216-3220	from	_	_	
18-3	3221-3228	healthy	_	_	
18-4	3229-3237	hamsters	_	_	
18-5	3238-3241	and	_	_	
18-6	3242-3246	from	_	_	
18-7	3247-3254	animals	_	_	
18-8	3255-3263	infected	_	_	
18-9	3264-3268	with	_	_	
18-10	3269-3273	263K	_	_	
18-11	3274-3281	scrapie	_	_	
18-12	3282-3286	were	_	_	
18-13	3287-3294	diluted	_	_	
18-14	3295-3297	10	_	_	
18-15	3297-3298	.	_	_	
18-16	3298-3301	sup	_	_	
18-17	3301-3303	.4	_	_	
18-18	3303-3304	-	_	_	
18-19	3304-3308	fold	_	_	
18-20	3309-3313	into	_	_	
18-21	3314-3315	a	_	_	
18-22	3316-3319	10%	_	_	
18-23	3320-3326	normal	_	_	
18-24	3327-3334	hamster	_	_	
18-25	3335-3340	brain	_	_	
18-26	3341-3351	homogenate	_	_	
18-27	3351-3352	.	_	_	

#Text=Samples were subjected to 48 PMCA cycles.
19-1	3353-3360	Samples	_	_	
19-2	3361-3365	were	_	_	
19-3	3366-3375	subjected	_	_	
19-4	3376-3378	to	_	_	
19-5	3379-3381	48	_	_	
19-6	3382-3386	PMCA	_	_	
19-7	3387-3393	cycles	_	_	
19-8	3393-3394	.	_	_	

#Text=After this first round of PMCA, a small aliquot of the amplified samples was taken and diluted 10-fold into more normal brain homogenate.
20-1	3395-3400	After	_	_	
20-2	3401-3405	this	_	_	
20-3	3406-3411	first	_	_	
20-4	3412-3417	round	_	_	
20-5	3418-3420	of	_	_	
20-6	3421-3425	PMCA	_	_	
20-7	3425-3426	,	_	_	
20-8	3427-3428	a	_	_	
20-9	3429-3434	small	_	_	
20-10	3435-3442	aliquot	_	_	
20-11	3443-3445	of	_	_	
20-12	3446-3449	the	_	_	
20-13	3450-3459	amplified	_	_	
20-14	3460-3467	samples	_	_	
20-15	3468-3471	was	_	_	
20-16	3472-3477	taken	_	_	
20-17	3478-3481	and	_	_	
20-18	3482-3489	diluted	_	_	
20-19	3490-3492	10	_	_	
20-20	3492-3493	-	_	_	
20-21	3493-3497	fold	_	_	
20-22	3498-3502	into	_	_	
20-23	3503-3507	more	_	_	
20-24	3508-3514	normal	_	_	
20-25	3515-3520	brain	_	_	
20-26	3521-3531	homogenate	_	_	
20-27	3531-3532	.	_	_	

#Text=These samples were again amplified by 48 PMCA cycles.
21-1	3533-3538	These	_	_	
21-2	3539-3546	samples	_	_	
21-3	3547-3551	were	_	_	
21-4	3552-3557	again	_	_	
21-5	3558-3567	amplified	_	_	
21-6	3568-3570	by	_	_	
21-7	3571-3573	48	_	_	
21-8	3574-3578	PMCA	_	_	
21-9	3579-3585	cycles	_	_	
21-10	3585-3586	.	_	_	

#Text=This procedure was repeated several times and PrP.sup.Sc generation was determined by Western blot analysis after PK digestion.
22-1	3587-3591	This	_	_	
22-2	3592-3601	procedure	_	_	
22-3	3602-3605	was	_	_	
22-4	3606-3614	repeated	_	_	
22-5	3615-3622	several	_	_	
22-6	3623-3628	times	_	_	
22-7	3629-3632	and	_	_	
22-8	3633-3643	PrP.sup.Sc	_	_	
22-9	3644-3654	generation	_	_	
22-10	3655-3658	was	_	_	
22-11	3659-3669	determined	_	_	
22-12	3670-3672	by	_	_	
22-13	3673-3680	Western	_	_	
22-14	3681-3685	blot	_	_	
22-15	3686-3694	analysis	_	_	
22-16	3695-3700	after	_	_	
22-17	3701-3703	PK	_	_	
22-18	3704-3713	digestion	_	_	
22-19	3713-3714	.	_	_	

#Text=In this study 10 rounds of PMCA to reach a final dilution of the original brain equivalent to 10.sup.-13 led to continuous formation of PrP.sup.Sc only when the initial inoculum was derived from scrapie-infected animals.
23-1	3715-3717	In	_	_	
23-2	3718-3722	this	_	_	
23-3	3723-3728	study	_	_	
23-4	3729-3731	10	_	_	
23-5	3732-3738	rounds	_	_	
23-6	3739-3741	of	_	_	
23-7	3742-3746	PMCA	_	_	
23-8	3747-3749	to	_	_	
23-9	3750-3755	reach	_	_	
23-10	3756-3757	a	_	_	
23-11	3758-3763	final	_	_	
23-12	3764-3772	dilution	_	_	
23-13	3773-3775	of	_	_	
23-14	3776-3779	the	_	_	
23-15	3780-3788	original	_	_	
23-16	3789-3794	brain	_	_	
23-17	3795-3805	equivalent	_	_	
23-18	3806-3808	to	_	_	
23-19	3809-3811	10	_	_	
23-20	3811-3812	.	_	_	
23-21	3812-3815	sup	_	_	
23-22	3815-3816	.	_	_	
23-23	3816-3817	-	_	_	
23-24	3817-3819	13	_	_	
23-25	3820-3823	led	_	_	
23-26	3824-3826	to	_	_	
23-27	3827-3837	continuous	_	_	
23-28	3838-3847	formation	_	_	
23-29	3848-3850	of	_	_	
23-30	3851-3861	PrP.sup.Sc	_	_	
23-31	3862-3866	only	_	_	
23-32	3867-3871	when	_	_	
23-33	3872-3875	the	_	_	
23-34	3876-3883	initial	_	_	
23-35	3884-3892	inoculum	_	_	
23-36	3893-3896	was	_	_	
23-37	3897-3904	derived	_	_	
23-38	3905-3909	from	_	_	
23-39	3910-3926	scrapie-infected	_	_	
23-40	3927-3934	animals	_	_	
23-41	3934-3935	.	_	_	

#Text=No PrP.sup.Sc was ever detected in the absence of PrP.sup.Sc inoculum, indicating that, even after 480 PMCA cycles, the system retains high specificity and no false positive samples were observed.
24-1	3936-3938	No	_	_	
24-2	3939-3949	PrP.sup.Sc	_	_	
24-3	3950-3953	was	_	_	
24-4	3954-3958	ever	_	_	
24-5	3959-3967	detected	_	_	
24-6	3968-3970	in	_	_	
24-7	3971-3974	the	_	_	
24-8	3975-3982	absence	_	_	
24-9	3983-3985	of	_	_	
24-10	3986-3996	PrP.sup.Sc	_	_	
24-11	3997-4005	inoculum	_	_	
24-12	4005-4006	,	_	_	
24-13	4007-4017	indicating	_	_	
24-14	4018-4022	that	_	_	
24-15	4022-4023	,	_	_	
24-16	4024-4028	even	_	_	
24-17	4029-4034	after	_	_	
24-18	4035-4038	480	_	_	
24-19	4039-4043	PMCA	_	_	
24-20	4044-4050	cycles	_	_	
24-21	4050-4051	,	_	_	
24-22	4052-4055	the	_	_	
24-23	4056-4062	system	_	_	
24-24	4063-4070	retains	_	_	
24-25	4071-4075	high	_	_	
24-26	4076-4087	specificity	_	_	
24-27	4088-4091	and	_	_	
24-28	4092-4094	no	_	_	
24-29	4095-4100	false	_	_	
24-30	4101-4109	positive	_	_	
24-31	4110-4117	samples	_	_	
24-32	4118-4122	were	_	_	
24-33	4123-4131	observed	_	_	
24-34	4131-4132	.	_	_	

#Text=Example 8
25-1	4133-4140	Example	_	_	
25-2	4141-4142	8	_	_	
